« Zurück
Startseite /
Anti-Human IL 12/23 (Briakinumab) Dylight® 488

Anti-Human IL 12/23 (Briakinumab) Dylight® 488

ArtNr	LEIN-LT511-100ug
Hersteller	Leinco Technologies
Menge	100 ug
Kategorie	Antibodies Primary Antibodies
Typ	Antibody Primary
Applikationen	FC, IF, FA
Clon	ABT-874
Specific against	Human (Homo sapiens)
Host	Human
Citations	1. Vsn, M. et al. (2016) VALUE IN HEALTH 19 PSS5:A123
NCBI	3593
ECLASS 10.1	32160702
ECLASS 11.0	32160702
UNSPSC	12352203
Versandbedingung	Gekühlt
Lieferbar
Manufacturer - Applications	Quality Tested by Leinco FC The suggested concentration for Briakinumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 10⁶ cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
Manufacturer - Category	Recombinant Antibodies>Biosimilar Recombinant Antibodies
Manufacturer - Targets	IL-12/IL-23 p40
Country of Origin	USA
Shipping Temperature	Next Day 2-8°C
Storage Conditions	This DyLight® 488 conjugate is stable when stored at 2-8°C. Do not freeze.
Product Description	Briakinumab is a human monoclonal antibody targets the p40 subunit shared by interleukins 12 and 23. IL-12 associates with IL-23α to form the heterodimeric cytokine IL-23. IL-23 is associated with various autoimmune inflammatory diseases, and is particularly highly expressed in psoriasis skin lesions. In addition, IL-23 is suspected to play a role in tumorigenesis. Briakinumab binds to and neutralizes human IL-12 and IL-23 (via their shared p40 subunit) and is being investigated for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. Anti-Human IL 12/23 (Briakinumab) utilizes the same variable regions from the therapeutic antibody Briakinumab making it ideal for research projects.
Background	Briakinumab is a human monoclonal antibody targets the p40 subunit shared by interleukins 12 and 23. IL-12 associates with IL-23α to form the heterodimeric cytokine IL-23. IL-23 is associated with various autoimmune inflammatory diseases, and is particularly highly expressed in psoriasis skin lesions. In addition, IL-23 is suspected to play a role in tumorigenesis. Briakinumab binds to and neutralizes human IL-12 and IL-23 (via their shared p40 subunit) and is being investigated for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. Anti-Human IL 12/23 (Briakinumab) utilizes the same variable regions from the therapeutic antibody Briakinumab making it ideal for research projects.
Additional Reported Applications For Relevant Conjugates	B N WB ELISA IP
Other Applications Reported In Literature	FA
PubMed	IL-12/IL-23 p40
Excitation Laser	Blue Laser (493 nm)
Manufacturer - Expression host	HEK-293
Manufacturer - Specificity	This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Briakinumab. Briakinumab recognizes both human IL12 and IL23 via IL-12/23p40. This product is for research use only.
FC Effector Activity	Active
RRID	AB_2893970
Concentration	0.2 mg/ml
Formulation	This DyLight® 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Antigen Distribution	IL-12 is produced by dendritic cells, macrophages, neutrophils, and human B-lymphoblastoid cells. IL-23 is mainly secreted by activated dendritic cells, macrophages or monocytes.
Immunogen	This antibody was produced by phage display technology.
Regulatory Status	Research Use Only (RUO). Non-Therapeutic.
Additional Information	Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

LEIN-LT511-100ug-safety-datasheet.pdf